Dr. Coe is a clinical pharmacologist and regulatory strategist specializing in CNS-active and psychedelic compounds, including MDMA and psilocybin. At Pinney Associates, she leads initiatives that bridge clinical innovation with regulatory compliance, focusing on compounds with complex benefit-risk profiles. She helps guide pharmaceutical sponsors through the intricacies of CNS drug development, from early-phase trials to post-marketing surveillance. Dr. Coe advises sponsors on clinical development plans, trial design, target product profiles, scientific due diligence, and emerging regulatory pathways for psychedelic therapies.

Dr. Robison is a board-certified psychiatrist and clinical researcher specializing in ketamine and psychedelic medicine. He has served as principal investigator on more than 250 CNS clinical trials, including pivotal studies of psilocybin, LSD, 5-MeO-DMT, and MDMA-assisted psychotherapy. His early work with IV ketamine for treatment-resistant depression helped lay the foundation for subsequent large-scale studies and approvals. Dr. Robison is first author of the 2025 JAMA Psychiatry publication on MindMed’s MM120 for generalized anxiety disorder and co-author of Usona’s Phase II psilocybin trial manuscript. He previously founded Cedar Clinical Research—one of the top-enrolling Phase II–III psychedelic trial sites—and Cedar Psychiatry.

Dr. Hough is a licensed clinical psychologist with over 15 years of experience in CNS research, specializing in psychedelic and addiction medicine. She has led studies involving psilocybin, LSD, MDMA, DMT, and ketamine, advancing treatments for depression, PTSD, and substance use disorders. Her expertise includes trial design, Human Abuse Liability research, and regulatory oversight for Schedule I compounds. At CRC, she leads scientific strategy and cross-functional collaboration supporting the development of novel psychiatric and psychedelic therapies. Before joining CRC, Dr. Hough directed addictions and psychedelic research at a national multi-site network, where she oversaw DEA submissions for clinical trials conducted across the U.S.